NewsBenzingaKeybanc mantiene la recomendación de sobreponderar sobre Five9 y eleva el precio objetivo a 34 dólares Keybanc mantiene la recomendación de sobreponderar sobre Five9 y eleva el precio objetivo a 34 dólares Benzinga 2026.11.06 14:22 (GMT+0) Open on Benzinga Other news Guggenheim Maintains Buy on Sphere Entertainment, Lowers Price Target to $175 Barclays Maintains Underweight on Manitowoc Co, Raises Price Target to $20 Guggenheim Maintains Buy on Curtiss-Wright, Lowers Price Target to $674 Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15 Guggenheim Maintains Buy on Acadia Healthcare Co, Raises Price Target to $41 Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19
